Cargando…

Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma

Pulmonary pleomorphic carcinoma (PPC) is a rare disease with a poor prognosis. Most patients with PPC are refractory to chemotherapy, whereas good responses to platinum‐based chemotherapy in combination with the anti‐angiogenesis agent bevacizumab have been reported. An 82‐year‐old man was diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishioka, Naoya, Kaneko, Yoshiko, Yamada, Tadaaki, Okura, Naoko, Hirai, Soichi, Takayama, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2018
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161404/ https://www.ncbi.nlm.nih.gov/pubmed/30275953 http://dx.doi.org/10.1002/rcr2.372

Ejemplares similares

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
por: Nishioka, Naoya, et al.
Publicado: (2018)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review
por: Okura, Naoko, et al.
Publicado: (2020)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
por: Katayama, Yuki, et al.
Publicado: (2020)

Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
por: Takayuki, Nakano, et al.
Publicado: (2018)

Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status
por: Kaneko, Yoshiko, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)
por: Sawada, Ryo, et al.
Publicado: (2023)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Impact of docetaxel plus ramucirumab in a second‐line setting after chemoimmunotherapy in patients with non‐small‐cell lung cancer: A retrospective study
por: Ishida, Masaki, et al.
Publicado: (2021)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use
por: Iijima, Yosuke, et al.
Publicado: (2020)

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer
por: Seto, Yurie, et al.
Publicado: (2022)

Comparison of the prognosis of symptomatic cerebral infarction and pulmonary embolism in patients with advanced non‐small cell lung cancer
por: Nakamura, Ryota, et al.
Publicado: (2023)

Tumor Neovascularization and Developments in Therapeutics
por: Katayama, Yuki, et al.
Publicado: (2019)

Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
por: Katayama, Yuki, et al.
Publicado: (2019)

Advanced G‐CSF‐producing non‐small cell lung cancer‐not otherwise specified, with favourable response to pembrolizumab monotherapy
por: Matsui, Yohei, et al.
Publicado: (2020)

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
por: Kanogawa, Naoya, et al.
Publicado: (2023)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2022)

Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
por: Imabayashi, Tatsuya, et al.
Publicado: (2019)

Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with high PD-L1 expression (SPIRAL-3D study)
por: Kawachi, Hayato, et al.
Publicado: (2023)

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review
por: Morita-Tanaka, Satomi, et al.
Publicado: (2023)

Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment
por: Uchino, Junji, et al.
Publicado: (2018)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma
por: Tamura, Yosuke, et al.
Publicado: (2015)

A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition
por: Kondo, Mayo, et al.
Publicado: (2018)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
por: Sako, Masahiro, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
por: Onoi, Keisuke, et al.
Publicado: (2020)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

Comprehensive molecular profiling of pulmonary pleomorphic carcinoma
por: Nagano, Masaaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1be95jg5f9qvg6u1u1bospcui